An interventional study of HBsAg RDT Women and Treatment by TDF if HBcrAg RDT positive in HBV Infection and Pregnancy, sponsored by ANRS, Emerging Infectious Diseases. Recruiting at 1 site in Vietnam. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by ANRS, Emerging Infectious Diseases · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To achieve global elimination of hepatitis B virus (HBV), it is crucial to eliminate HBV mother-to-child transmission (MTCT) by ensuring high coverage of birth dose vaccine and expanding the adoption of peripartum antiviral prophylaxis (PAP) by tenofovir. Current international guidelines require hepatitis B surface antigen (HBsAg)-positive pregnant women to undergo viral load (VL) quantification to identify those at high risk (VL ≥200,000 IU/mL) who should receive PAP. However, VL testing remains inaccessible in many low- and middle-income countries (LMICs), particularly in rural areas. Consequently, in the forthcoming guidelines, the WHO is going to issue a conditional recommendation for administering PAP to all HBsAg-positive women lacking access to VL testing. Although this universal strategy may appear promising for simplifying the diagnostic process, it may result in overtreating the majority of HBsAg-positive pregnant women, estimated at 85% in Africa and 70% in Asia, for whom birth dose vaccine is likely sufficient. Moreover, the real-world applicability of this strategy in LMICs has never been formally tested.
As an innovative alternative, the adoption of a rapid point-of-care test for hepatitis B core-related antigen (HBcrAg-RDT) is proposed to identify women eligible for PAP.This test requires only a drop of capillary blood, eliminating the need for electricity or centrifugation, and can provide a reliable result within 45 minutes. Compared to the universal strategy, HBcrAg-RDT strategy is expected to be less expensive and could prevent unnecessary tenofovir exposure for both women and their fetuses. Our aim is to establish the non-inferiority of the HBcrAg-RDT strategy, in comparison to the universal strategy, in terms of effectiveness, defined as the reduction in maternal VL at the time of childbirth, a main driver of the MTCT risk. This will be approached through a multidisciplinary framework integrating health economics, implementation science, and health policy analysis.
I) Methodology and Study Design
The study combines two components:
I. Core Research Study Study Design Two-Arm Parallel, Cluster-Randomized Trial Design, Open-Label, Non-Inferiority Trial 1:1 Allocation Ratio 1:1 Arm 1: Intervention Group (Selective Strategy) HBsAg-positive women → Tested for HBcrAg RDT → TDF treatment if HBcrAg positive.
Arm 2: Control Group (Universal Strategy) HBsAg-positive women → Immediate TDF treatment
Clusters Randomization unit: Primary Health Centers (PHCs) or rural hospitals Total clusters: 80 (40 per group, 16 clusters per country)
Participants Total participants: 3200 HBsAg-positive women 1600 women per group → 640 women per country → 40 per cluster
Key eligibility criteria for clusters include:
II. The Social Science component:
The social sciences component of the study will be conducted in only 2 countries (Cambodia and Ivory Coast) and includes three key sub-studies:
A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers.
Additionally, a qualitative assessment of the two strategies' acceptability, alongside a health policy analysis, will be conducted in Togo to enrich the study's contextual understanding. This initiative will also enhance the partner team's social science research capacity through targeted training and skill development in qualitative research for students and early-career researchers.
II) Intervention:
Medication: Tenofovir Disoproxil Fumarate (TDF); Administration Route: Oral Dosage: 300 mg/day or 300 mg every 2 days (if creatinine clearance is 30-50 ml/min)
Preventive treatment:
III) Statistical methods
Core research study. The investigators predict that with the universal strategy, the proportion of women meeting the primary endpoint would be 78%. They chose a non-inferiority margin of 10% when comparing the HBcrAg-RDT strategy to the universal strategy. This indicates that a 68% success rate would be accepted for the same primary endpoint under the worst-case HBcrAg-RDT strategy.
They plan to recruit 40 HBsAg-positive women in each PHC. With a coefficient of variation between clusters of 0.143, derived from the assumptions, the trial requires 40 clusters per group, totaling 80 clusters of 40 HBsAg-positive women each, for 90% power at two-sided 5% (2.5% one-sided) significance to show non-inferiority within a margin of 10%.
Social Science quantitative data:
The sample size for the social science data is based on the proportion of women with good knowledge of hepatitis B, 90% power, two-sided 5% significance, and 20% loss to follow-up at the 9-month postpartum visit. Assuming 23% and 29% of women having good knowledge of hepatitis B at inclusion and the 9-month postpartum visit, respectively, overall for both strategies, with a correlation coefficient before-after of 0.15, 32 clusters (16 per country) of 40 women each (totaling 1280 participants) will be needed to show significant differences in the proportion of women with good knowledge of hepatitis B between inclusion and the 9-month postpartum visit (overall, considering both strategies together).
1,048 studies on the registry are indexed under Hepatitis B; 141 are open to participants now.
This study's planned enrollment of 3,200 is above the median of 145 across 758 interventional studies indexed under Hepatitis B.
Browse Hepatitis B studies →ANRS, Emerging Infectious Diseases is the lead sponsor of 215 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Having at least one of the following criteria indicatives of the third trimester of pregnancy:
The reported gestational age is ≥28 weeks, based on the last menstrual period (LMP) if known.
Fetal biometry (e.g., head circumference, femur length) on ultrasound suggests a gestational age of ≥28 weeks.
Symphysis-fundal height (SFH) measurement of ≥ 28 cm which corresponds to approximately 28 weeks of gestation.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pregnant women who test positive for HBsAg will initiate TDF preventive treatment on the same day of their visit. Their child/children will be enrolled in the study until 9 months.
Diagnostic Test: HBsAg RDT Women · Drug: Treatment by TDF · Other: Social sciences component · Diagnostic Test: HBsAg RDT Infants
Pregnant women who test positive for HBsAg will be tested for HBcrAg RDT on the same day of their visit, and those who test positive will initiate TDF preventive treatment on the same date.Their child/children will be enrolled in the study until 9 months.
Diagnostic Test: HBsAg RDT Women · Drug: Treatment by TDF if HBcrAg RDT positive · Other: Social sciences component · Diagnostic Test: HBsAg RDT Infants
HBsAg will be screened using finger-stick capillary blood during the ANC visit, simultaneously with the HIV test
300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
300mg per day or 300 mg every 2 days (if créatinine clearance is 30-50ml/min)
The social sciences component only in Cambodia and Ivory Coast. 3 key sub-studies: i) a socio-economic and behavioral study ii) a health economic evaluation study, and iii) a health policy study. A mixed-methods approach will be used, including qualitative interviews and quantitative questionnaires among pregnant women and healthcare workers
At 9 months, all infants will be tested for HBsAg; HBsAg-positive infants will undergo HBV DNA testing, and DBS will be collected for biobank storage.
Percentage of HBsAg-positive women with HBV DNA <200,000 IU/mL at the time of delivery
The primary endpoint will be the percentage of HBsAg-positive women who present at healthcare facilities for delivery and have an HBV DNA \<200,000 IU/mL at the time of delivery.
Time frame: Delivery
Percentage of infants positive for HBsAg
Time frame: At 9 months of life
Percentage of women eligible for PAP who started TDF
Time frame: At screening
Percentage of women eligible for PAP who completed TDF prophylaxis
Time frame: up to 40 weeks of gestation
Percentage of women with adherence >90% at each study visit based on pill counts and self-report
Time frame: from inclusion to delivery, max 40 weeks
Percentage of infants receiving HepB-BD
Time frame: up to 9 months
Percentage of infants with a complete HepB vaccination schedule
Time frame: up to 9 months
Percentage of women or infants with a serious adverse event (SAE) leading to death, or leading to treatment discontinuation up to delivery and Adverse Events of Special Interest
Time frame: through study completion, an average of 27 months
Percentage of women who underwent liver disease assessment and factors associated with retention in care.
Time frame: At 3 months postpartum
Percentage of women eligible for long-term TDF treatment
Time frame: At 3 months post-partum
Accuracy (sensitivity, specificity, positive and negative predictive values) of the simplified score (HBcrAg-RDT & ALT) to predict eligibility for the long-term TDF treatment
Time frame: At inclusion and 3 months after delivery
Communicative Health Literacy (COM_HL) on hepatitis B and related risks, empowerment, and health literacy among women and healthcare workers and factors associated
Minimum total score = 5 Maximum total score = 25 Low score: Indicates low communicative literacy. High score : Reflects a good ability to interact effectively in a healthcare context
Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery
Measures of the disclosure of HBV status among women and experience of sharing HBV status anf factors associated.
Percentage of women who disclosed their HBV status to their partner and HBV disclosure score/moral support and discrimination scales
Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery
Percentage of partners and children who have been screened for HBV
Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery
Measures of perceived health and quality of life among women, the internalized stigma of mental illness and factors associated.
Time frame: At 3-time points: inclusion, 6-8 weeks after delivery and 9 months after delivery
Acceptability for each strategy among healthcare workers, assessed using a scale adapted from Sekhon et al., 2022 to the intervention.
Minimal total score= 0 Maximal total score= 100 Low score indicates low acceptability High score indicates high acceptability
Time frame: Before HCW training and at the end of the study (18-24 month after the study starts)
. Measures of preferences of healthcare providers between the two strategies and associated factors
Declared preferences of HCW between theoretical scenarios exhibiting various characteristics (time to get a diagnostic in minutes, cost for women in dollars, specificity and sensibility of the test in percentage)
Time frame: Before HCW training and at the end of the study (18-24 month after the study starts)
.Cost per pregnant woman of the universal and of the targeted strategy, from the moment they are screened positive with the HBAgS (RDT)
Costs will be estimated based on a societal approach, including all expenses for the healthcare system and the costs (direct and indirect) for the women and their households, and will be estimated using a dedicated data collection tool administrated during the duration of the project, relying on a micro-costing approach (see section 3.2.2 of the protocol, Health Economic Evaluation).
Time frame: until 9 months after delivery
Incremental cost-effectiveness ratio (ICER)
ICER wil be calculated as the difference in costs between the two strategies (incremental cost) divided by the difference in health benefits (infections avoided and mortality avoided between the two strategies). The ICER will be expressed as an additional cost (in dollars) per infection avoided. Lower ICER indicates greater cost-effectiveness of the assessed strategy.
Time frame: At the end of follow_up after 27 months
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Nov 2028, 27 months after the start.
Of 62 non-industry interventional studies with no phase under Hepatitis B, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 27 months is close to that.
Counting every sponsor, half of 68 studies reached it within 29 months; a quarter within 11 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Nov 2025 → Aug 2026, primary completion Nov 2026 → Nov 2028 and completion Jan 2028 → Nov 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ANRS, Emerging Infectious Diseases →